ODTX earnings: next report 2026-09-16, real EPS beat/miss history, analyst consensus Buy, P/E -3.45. Updated 2026-07-23.
Odyssey Therapeutics (ODTX) Research Hub
Odyssey Therapeutics (ODTX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 24.63 USD (+0.49%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -3.45, market cap 0.55B. This hub links to the full technical, earnings and options research available for ODTX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 24.63 USD (+0.49%) |
| 52-week range | 15.5 USD – 29.05 USD |
| Trend regime | Range |
| 14-day RSI | 59.8 (Bullish) |
| Trailing P/E | -3.45 |
| Market cap | 0.55B |
| Dividend yield | 0.00% |
| Next earnings | 2026-09-16 |
Available research for ODTX
Covered Call on ODTX: how it works, illustrative setup around the real 24.63 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ODTX: how it works, illustrative setup around the real 24.63 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ODTX: how it works, illustrative setup around the real 24.63 USD price, max profit/loss, breakeven and when to use it. Educational.
ODTX technical analysis: range, last 24.63 USD, RSI 59.8, 52w range 15.5 USD–29.05 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ODTX in?
Odyssey Therapeutics (ODTX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ODTX in an uptrend or downtrend?
As of 2026-09-11, ODTX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ODTX's trailing P/E ratio?
ODTX's trailing P/E is -3.45, with a market cap of 0.55B. See the earnings research page for full valuation detail.
When does ODTX next report earnings?
ODTX is next scheduled to report earnings on 2026-09-16, with a consensus EPS estimate of -0.91214 USD.